Applied Biosystems introduces four new Gene Signature Panels for use in PCR applications

By E. Janene Geiss

Philadelphia, Dec. 1 - Applied Biosystems, an Applera Corp. business, announced Thursday the introduction of four new Gene Signature Panels as part of its TaqMan Low Density Array product line for real-time PCR applications.

The new arrays include the Human G Protein-Coupled Receptors Panel (GPCR), Human Protein Kinase Panel, Mouse Immune Panel and Human Endogenous Controls Panel, according to a company news release.

The Human GPCR and Human Protein Kinase Panels are important tools for drug target screening and pharmacogenomics research studies, officials said.

The Mouse Immune Panel contains genes known for their involvement in inflammation, cancer and cell proliferation, making it a significant tool for disease association studies, while the Endogenous Control Panel gives researchers a way to select the most appropriate controls for experiments, officials said.

Applied Biosystems TaqMan Low Density Arrays (TLDA) are 384-well micro fluidic cards designed for analyzing gene expression patterns in many samples across a defined set of gene targets. TaqMan Low Density Arrays streamline reaction set-up, reduce reagent consumption and require no liquid-handling robotics, officials said.

"TaqMan Low Density Arrays have always been ideal for a variety of drug discovery screening applications," said William V. Murray, division president of molecular biology for Applied Biosystems.

"With our new Gene Signature Panels, researchers will now be able to combine the high level of performance of TLDA with the convenience of pre-configured panels specifically developed for key applications, including Human GPCR, Human Protein Kinase, Mouse Immune and Human Endogenous Controls," Murray added.

Applera Corp., in Foster City, Calif., consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software and services. The Celera Genomics Group is engaged principally in the discovery and development of targeted therapeutics for cancer, autoimmune and inflammatory diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.